# LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients

> **NCT02077257** · PHASE4 · UNKNOWN · sponsor: **Committee of Cardio-Cerebral-Vascular Diseases of GSC** · enrollment: 1060 (estimated)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT02077257
- **Lead sponsor:** Committee of Cardio-Cerebral-Vascular Diseases of GSC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2015-12
- **Final completion:** 2016-05
- **Target enrollment:** 1060 (ESTIMATED)
- **Last updated:** 2014-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077257, "LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02077257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*